B+
Bull case
25%
Probability
Target price
$15.00
Analysis reference price unavailable
Analysis 2026-10-23 · RankAlpha Sentiment Codex
STRO
Sutro BiopharmaDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Early STRO-004 activity, STRO-006 first dosing, and a stated $164.3 million June 30 cash-and-securities balance support a funded multi-program development case. Management expected that balance to support operations into at least the second quarter of 2028 [#SEC-8K-2026-08-12] [#PR-2026-10-21].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -34.1.
What can break
R&D spending, future financing needs, and dilution could erode the apparent cash-to-market-cap support.
Momentum
2
Value
41
Sentiment
64
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $10.00 · Bull $15.00 · Bear $6.00Analysis 2026-10-23; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-23 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $47.23
Why
Momentum2 · Δ7d -0.2
Value41 · Δ7d -0.1
Sentiment64 · Δ7d -34.1
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -34.1.
Contradictions & invalidation
- • R&D spending, future financing needs, and dilution could erode the apparent cash-to-market-cap support.
- • STRO-004 response durability, optimal dose, and safety remain unresolved after a small, early Phase 1 dataset [#SEC-8K-2026-08-12].
- • STRO-004 responses are preliminary, STRO-006 has no human efficacy data, and clinical timelines or spending could change.
Catalyst clock
2026-12-31
STRO-227 IND submission
Lead driver: Sentiment · See AI snapshot
Momentum
2
8% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-2.1
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
64
45% active weight
Current posture
7d trendSoftening
Δ7d
-34.1
Δ21d
+3.1
Why this grade
Composite grade D. Momentum 2.2 / Value 40.6 / Sentiment 63.6
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-23. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$10.00
Analysis reference price unavailable
Analysis 2026-10-23 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$6.00
Analysis reference price unavailable
Analysis 2026-10-23 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$154.7M
Beta
1.55
Shares Out
16.58M
P/E (TTM) · Derived
-0.4
P/S (TTM)
0.88
P/FCF (TTM) · Derived
-0.71
Rev YoY
-84.6%
EPS YoY
+71.0%
Gross Margin
+86.7%
Op Margin
-288.5%
Net Debt
$93.78M
Current Ratio
3.32
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data